Ponatinib-Associated Cutaneous Eruptions—A Case Series and Review of Clinicopathologic Findings

Abstract

Ponatinib is a third-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Cutaneous toxicities are a commonly reported side effect of ponatinib treatment with "rash" being one of the most common. Specific subtypes are infrequently reported, but include hyperkeratotic, folliculocentric, ichthyosiform, and pityriasis rubra pilaris-like eruptions. Herein, we highlight the clinicopathologic features of 2 cases of ponatinib-induced pityriasis rubra pilarislike eruptions. We also classify the clinical and histopathologic features of all previously reported ponatinib-associated eruptions in the literature and discuss treatment and potential diagnostic pitfalls.

Selpercatinib induced intestinal lymphangiectasia in RET fusion positive metastatic non-small cell lung cancer

“…Similarly, Masui et al (2022) reported a 62-year-old male patient diagnosed with renal cell carcinoma with metastasis that developed intestinal lymphangiectasia four years after starting treatment with Pazopanib [5] . TKIs have also been reported to cause dermal lympgangiectasia [6] , upper eyelid lymphangiectasia [7] and chylothorax [8] .…”

Delayed Presentation of Pityriasis Rubra Pilaris in a Patient on Treatment With Ponatinib

“…In rare cases, medications such as imatinib and ponatinib have been implicated [ 1 ]. There have been 12 reported cases of ponatinib-induced PRP to date, and here we present the thirteenth case with a significantly delayed presentation [ 2 , 3 ].…”